Skip to main content
SpringerLink
Log in

Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

IGFBP2 is one of the highly expressed genes in glioblastoma (GBM). It has both IGF dependent and independent activities. IGF independent actions are mediated by the activation of integrin signalling through its RGD motif present at C-terminal domain. One of the actions of IGFBP2 is to regulate β-catenin by the inactivation of GSK3β, which preferentially accumulates in the cytoplasm. The mechanism of nuclear β-catenin regulation by IGFBP2 and role of cytoplasmic β-catenin is not clear. We aimed to understand the mechanism in GBM cell lines.

Methods

The gene expression studies were performed by RT-PCR, western blot analysis; the knockdown of genes was performed by shRNA transfection; RNAIP and luciferase reporter assays were utilized to study the cytoplasmic regulation of genes by β-catenin; neurosphere assays were performed to study the stemness of cells.

Results

IGFBP2 overexpression or treatment in GBM cells regulates β-catenin, TRIM33 (E3 ubiquitin ligase) and Oct4 genes. TRIM33 was induced by IGFBP2. β-catenin was found to accumulate predominantly in the cytoplasm and nuclear β-catenin was depleted by IGFBP2 induced TRIM33. IGFBP2 regulated cytoplasmic β-catenin binds to 3’ UTR of Oct4 RNA. IGFBP2 was also able to induce stemness of glioma cells.

Conclusions

IGFBP2 induces TRIM33 which regulates the nuclear β-catenin protein. In addition, IGFBP2 stabilizes the cytoplasmic β-catenin which is involved in the regulation of Oct4 transcript and consequently induction of stemness of glioma cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of data and material

Yes, will be provided when requested.

References

  1. Ostrom QT et al (2014) The epidemiology of glioma in adults: a state of the science review. Neuro-Oncology 16:896–913

    Article  CAS  Google Scholar 

  2. Ostrom QT et al (2016) Neuro-oncology system tumors diagnosed in the United States in 2009–2013. Neuro-oncology. https://doi.org/10.1093/neuonc/now207

    Article  PubMed  PubMed Central  Google Scholar 

  3. Agnihotri S, Burrell KE, Wolf A (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp. https://doi.org/10.1007/s00005-012-0203-0

    Article  Google Scholar 

  4. Pickard A, McCance DJ (2015) IGF-binding protein 2—oncogene or tumor suppressor? Front Endocrinol 6:1–8

    Article  Google Scholar 

  5. Shimasaki S, Ling N (1991) Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res 3:243–266

    Article  CAS  Google Scholar 

  6. Wang GK, Hu L, Fuller GN, Zhang W (2006) An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281:14085–14091

    Article  CAS  Google Scholar 

  7. Liu Y et al (2019) IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma. Oncogene 38:1815–1831

    Article  CAS  Google Scholar 

  8. Deramaudt TB et al (2011) FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol Biol Cell 22:964–975

    Article  CAS  Google Scholar 

  9. Lu H et al (2013) IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther 12:2864–2873

    Article  CAS  Google Scholar 

  10. Patil SS et al (2016) Insulin-like growth factor binding protein-2 regulates β-catenin signaling pathway in glioma cells and together contributes to poor patient prognosis. Neuro-Oncology 18(11):1487–1497

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Fukushima T, Kataoka H (2007) Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res 27:3685–3692

    CAS  PubMed  Google Scholar 

  12. Han S, Li Z, Master LM, Master ZW, Wu A (2014) Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer 111:1400–1409

    Article  CAS  Google Scholar 

  13. Hsieh D, Hsieh A, Stea B, Ellsworth R (2010) IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun 397:367–372

    Article  CAS  Google Scholar 

  14. Sehgal P et al (2013) Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis. Mol. Cancer 12:63

    Article  CAS  Google Scholar 

  15. Pu P et al (2009) Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 16:351–361

    Article  CAS  Google Scholar 

  16. Nager M et al (2012) β-catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract 2012:192362

    PubMed  PubMed Central  Google Scholar 

  17. Zhang N et al (2011) FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20:427–442

    Article  CAS  Google Scholar 

  18. Xue J et al (2015) Tumour suppressor TRIM33 targets nuclear β-catenin degradation. Nat Commun 6:1–16

    CAS  Google Scholar 

  19. Chen L et al (2011) β-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma. Int J Oncol 39:883–890

    CAS  PubMed  Google Scholar 

  20. Cadigan KM, Waterman ML (2012) TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol 4:1–22

    Article  Google Scholar 

  21. Ben-porath I et al (2010) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumor. Nat Genet 40:499–507

    Article  Google Scholar 

  22. Hee KL et al (2007) β-catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells. Cancer Res 67:9315–9321

    Article  Google Scholar 

  23. Kim I, Kwak H, Lee HK, Hyun S, Jeong S (2012) β-catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3′-UTR and interacts with HuR in colon cancer cells. Nucleic Acids Res 40:6863–6872

    Article  CAS  Google Scholar 

  24. Holla S et al (2016) MUSASHI-mediated expression of JMJD3, a H3K27me3 demethylase, is involved in foamy macrophage generation during mycobacterial infection. PLoS Pathog 12:1–25

    Article  Google Scholar 

  25. Li T et al (2020) IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene 39:2243–2257

    Article  CAS  Google Scholar 

  26. Yau SW, Azar WJ, Sabin MA, Werther GA, Russo VC (2015) IGFBP-2—taking the lead in growth, metabolism and cancer. J Cell Commun Signal 9:125–142

    Article  Google Scholar 

  27. Huang LE et al (2017) IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget 8:191–202

    Article  Google Scholar 

  28. Shen F, Song C, Liu Y, Zhang J, Wei Song S (2019) IGFBP2 promotes neural stem cell maintenance and proliferation differentially associated with glioblastoma subtypes. Brain Res 1704:174–186

    Article  CAS  Google Scholar 

  29. Huynh H et al (2011) IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells. Blood 118:3236–3243

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the help from Prof. G. Subba Rao, for the generous gift of shRNAs and Confocal facility at the Division of Biological Sciences, Indian Institute of Science. BKV received fellowship from University Grants Commission, New Delhi and PK is a recipient of Indian National Science Academy Senior Scientist fellowship.

Funding

Department of Biotechnology, Govt. of India; DBT-IISc partnership program to PK

Author information

Authors and Affiliations

  1. Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Biological Sciences Building, Bangalore, 560012, India

    Brijesh Kumar Verma & Paturu Kondaiah

Authors
  1. Brijesh Kumar Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paturu Kondaiah
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BKV and PK planned the experiments, BKV executed, BKV and PK: Data analysis and manuscript writing.

Corresponding author

Correspondence to Paturu Kondaiah.

Ethics declarations

Conflicts of interest

No conflict of interest for any authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verma, B.K., Kondaiah, P. Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma. J Neurooncol 149, 209–217 (2020). https://doi.org/10.1007/s11060-020-03596-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-020-03596-4

Keywords

Search

Navigation